All News

Researchers outline the significant role IL-37 plays in psoriasis, and other skin and connective tissue diseases, suggesting the need for further research, according to a review.

Individuals’ susceptibility to genetic and epigenetic factors may be responsible for the transformation of episodic migraine to chronic migraine in some patients, according to a new review published in The Journal of Headache and Pain.

The small molecule from BeyondSpring is currently in late-stage clinical development in non–small cell lung cancer and for prevention of chemotherapy-induced neutropenia.

Rising drug costs in the United States are a pressing concern not only for patients who need to receive those drugs, but also for employers. The Employers’ Prescription for Affordable Drugs is a coalition that aims to tackle this problem by working with policy makers and stakeholders to encourage and facilitate more transparency, competition, and value in the healthcare system.

A new study released in Cell Reports found a common gut bacterium that boosts digestive health may also help guard against Parkinson disease.

As part of our anniversary celebration, today we launch “Paper of the Week,” which will look back at some of the most influential research articles and commentary that have appeared in The American Journal of Managed Care® over the past 25 years, and why they are important today.

Researchers highlight new therapeutic attempts and potential future approaches to treating idiopathic pulmonary fibrosis, a chronic, fibrosing idiopathic interstitial lung disease.

This week, the top managed care stories included AJMC®’s annual health information technology issue; a debate over the value of PrEP; rates of heart disease falling among survivors of childhood cancer.

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

Along with weight loss, exercise, and nutrition, employers now target sleep improvements in employees; a Republican member of the FTC supports Medicare drug price negotiations; sepsis is likely responsible for 20% of deaths worldwide.

For patients with multiple sclerosis, ketogenic diets and fasting diets may be potentially safe and inexpensive complementary treatment options. However, additional clinical studies and data are needed to prove this theory.

Sickle cell disease is the most common red blood cell disorder in the United States, having been diagnosed in approximately 100,000 African Americans alone. The lack of oxygen from sickle cell buildup can lead to acute pain crises, joint and organ damage, stroke, and reduced life expectancy.

A new study published in PLoS One is the first of its kind to systematically describe and quantify the difference between measured curvature and actual retinal contour of the eye using optical coherence tomography.

Compared with other biologics approved for psoriasis treatment, excluding recently approved biologics, ixekizumab and brodalumab were shown to have greater cumulative clinical benefit for patients with psoriasis, according to study findings.

Tracheobronchial colonization by pseudomonas aeruginosa was shown to increase the mortality risk of outpatients with chronic obstructive plumonary disease (COPD) by 47%, according to study results.

Since 2016, racial and ethnic healthcare disparities have not improved; a new method of "reanimating" hearts from recently deceased donors for transplants is being tested; the new decade prompts concerns about an aging population.

While the number of survivors who had cardiotoxic treatments increased, the doses they received decreased. Radiation exposure fell from 77% in the 1970s to 40% in the 1990s.

A study investigating the clinical phenotype of acute graft-versus-host disease (GVHD) in children reveals that one-third of pediatric patients with the disease are not successfully treated with steroids as a primary GVHD therapy.

The implementation of the Smart Snacks in School standards in 310 public schools resulted in healthier dietary intakes among students compared with those without the standards, according to a JAMA study published January 15.

The costs of disease-modifying drugs for patients with multiple sclerosis (MS) have almost tripled in 7 years, even with the introduction of generic options in the market, according to a study published by Neurology, the medical journal of the American Academy of Neurology.

In the evolving treatment landscape for sickle cell disease, current standards of treatment involve 4 drugs that have been FDA approved, with further innovations and limitations adding to the paradigm of care.

A systematic review and meta-analysis of data collected from observational cohort studies reveals several clinical and sociodemographic factors are predictors of chronic migraine.

Physician burnout continues to be pervasive and differs by generation; more opioid doses flooded the market than originally believed; the FDA drug approval rate is speeding up.

The group of patients with high CD154-postive mast cells had lower overall 5-year survival rates than the low CD154-positive group.

The median time to first intravenous therapy for acute heart failure (AHF) is 3.0 hours in North America compared with 1.2 hours in all other regions, in the International Registry to Assess Medical Practice with Longitudinal Observation for Treatment of Heart Failure. Treatment timing and differences may affect outcomes in patients with AHF.

Sleep duration was found to reflect the profile of specific circulating microRNAs in the blood of school-aged children and adolescents, indicating the potential efficacy of a blood test to examine those at risk of negative health outcomes related to insufficient sleep, according to study findings.

Researchers outlined a comprehensive review of the common mechanisms through which interleukin-17 (IL-17) is considered a molecular target for developing novel biological therapies in several different fields of medicine, according to report findings.

Immunotherapy continues to be increasingly used for treating multiple myeloma (MM) with a recent report providing an overview of monoclonal antibodies (mAbs) currently approved for treating MM, as well as, compounds that are under investigation.